EyePoint Pharmaceuticals, Inc. completed enrollment in the Phase 2 PAVIA clinical trial for EYP-1901, exceeding the target of 60 patients with a total of 77 patients.
AI Assistant
EYEPOINT PHARMACEUTICALS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.